Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 11,161 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohort study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess PDM608 in Healthy Adult Subjects

NCT05950906
View directory record Official record
Conditions
Parkinson Disease
Interventions
PDM608, Placebo
Drug
Lead sponsor
Calibr, a division of Scripps Research
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 31, 2026, 2:55 AM EDT
Terminated Phase 1 Interventional Results available

KZR-261 in Subjects With Advanced Solid Malignancies

NCT05047536
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumor
Interventions
KZR-261
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 31, 2026, 2:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064
View directory record Official record
Conditions
Recurrent or Metastatic Solid Tumors
Interventions
Ifinatamab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Olanzapine in Patients With Advanced Cancer and Weight Loss

NCT00489593
View directory record Official record
Conditions
Advanced Cancer, Weight Loss
Interventions
Olanzapine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 31, 2026, 2:55 AM EDT
Recruiting Phase 2 Interventional

Ulixertinib in People With Histiocytic Neoplasms

NCT06411821
View directory record Official record
Conditions
Histiocytic Neoplasms
Interventions
Ulixertinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Rochester, Minnesota • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors

NCT00093821
View directory record Official record
Conditions
Childhood Chronic Myelogenous Leukemia, Childhood Desmoplastic Small Round Cell Tumor, Disseminated Neuroblastoma, Metastatic Childhood Soft Tissue Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions
tanespimycin, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 31, 2026, 2:55 AM EDT
Active, not recruiting No phase listed Observational

Delirium in Children Undergoing Stem Cell Transplantation

NCT04937400
View directory record Official record
Conditions
Stem Cell Transplant Complications, Delirium
Interventions
Daily screening for delirium
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
Up to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 31, 2026, 2:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07732400
View directory record Official record
Conditions
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions
VV-14303
Genetic
Lead sponsor
Kriya Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chandler, Arizona • Lady Lake, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

NCT02100436
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

XmAb5871 Bioavailability Study

NCT02867098
View directory record Official record
Conditions
Healthy Volunteers
Interventions
XmAb5871
Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 31, 2026, 2:55 AM EDT
Completed No phase listed Observational

Diabetes Group Visits

NCT01000363
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chamblee, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 31, 2026, 2:55 AM EDT
Active, not recruiting No phase listed Observational

LITMUS Imaging Study

NCT05479721
View directory record Official record
Conditions
NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver
Interventions
Not listed
Lead sponsor
University of Oxford
Other
Eligibility
18 Years to 100 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

NCT06469151
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5148, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Anniston, Alabama • Glendale, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 31, 2026, 2:55 AM EDT
Active, not recruiting Phase 3 Interventional

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

NCT03803553
View directory record Official record
Conditions
Metastatic Colon Cancer, Stage III Colon Cancer
Interventions
FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol, Encorafenib/Binimetinib/Cetuximab Protocol, Trastuzumab + Pertuzumab
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Study of Nesvacumab (REGN910/ SAR307746)

NCT01271972
View directory record Official record
Conditions
Solid Tumors
Interventions
nesvacumab (REGN910/ SAR307746)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
San Francisco, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Oct 31, 2026, 2:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

NCT07389239
View directory record Official record
Conditions
Ovarian Cancer, Advanced Malignant Solid Tumor
Interventions
Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII, Aldesleukin
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Results available

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

NCT03664804
View directory record Official record
Conditions
Huntington's Disease
Interventions
No Study Drug was Administered in this Study
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Englewood, Colorado • Washington D.C., District of Columbia • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

NCT02514447
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Trilaciclib, Placebo, Topotecan
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
35
States / cities
Hot Springs, Arkansas • Rogers, Arkansas • Corona, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 31, 2026, 2:55 AM EDT
Withdrawn No phase listed Observational

Remote Tracking of Epilepsy Patients

NCT01130649
View directory record Official record
Conditions
Epilepsy
Interventions
HealthBuddy
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors

NCT01999738
View directory record Official record
Conditions
Solid Tumors, Non Small Cell Lung Carcinoma
Interventions
EC1456 and EC20
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
16
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 31, 2026, 2:55 AM EDT
Completed No phase listed Observational

The xDAPT External Validation Study

NCT06736626
View directory record Official record
Conditions
Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
Percutaneous coronary intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 31, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

NCT03780517
View directory record Official record
Conditions
Advanced Nonhaematologic Malignancies
Interventions
BOS172738
Drug
Lead sponsor
Boston Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 31, 2026, 2:55 AM EDT
Completed No phase listed Observational

Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers

NCT00440908
View directory record Official record
Conditions
End Stage Renal Disease, Inflammation
Interventions
Not listed
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
2
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2008 · Synced Oct 31, 2026, 2:55 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

NCT03693625
View directory record Official record
Conditions
Urticaria
Interventions
GDC-0853
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 31, 2026, 2:55 AM EDT